Most founders chase the next big app or AI model. But what if the real money is in the dirty, obscure, indispensable inputs no one talks about? Shaan Puri just blew the lid off one: the non-human primate (NHP) testing industry, an overlooked pillar of drug development that quietly became a $4 billion-a-year business.

Key Takeaways

  • More than 20% of all drugs, from everyday pills to vaccines, are tested on monkeys because they are the closest biological proxy to humans before trials. It's a non-negotiable step in pharma.
  • The price of a single lab monkey exploded from $2,000 to $50,000 during COVID due to unprecedented demand for testing and a sudden supply cut from China.
  • China, which once supplied 60% of the world's NHPs, abruptly halted exports, creating a global supply shock that crippled drug development timelines.
  • Charles River Labs, a $4 billion revenue giant doing research testing as a service, responded by buying its own monkey breeding facilities for $500 million just to secure supply.
  • The industry is messy, involving global sourcing, ethical debates, and even arrests (like Cambodia's wildlife director for fraudulent tagging), proving even obscure inputs have wild, high-stakes supply chains.

The Hidden Engine of Drug Development

Forget the gleaming labs and biotech breakthroughs for a second. The reality of drug development starts with something far less glamorous: animal testing. Shaan Puri points out that for over one-fifth of all drugs, from vaccines to new treatments, the crucial testing phase involves non-human primates. He says, “more than 20% of all drugs are tested on monkeys.” These animals are not just an option; they're an essential, regulatory-required step because their biology is a close match for human trials.

This isn't a small-time operation. It's an entire industrial apparatus, and it runs in the background of every major pharmaceutical company. The sheer scale and reliance on this input mean that any disruption sends shockwaves through a multi-trillion-dollar industry.

When Supply Chains Break: A $50,000 Monkey

Then came COVID. The world needed vaccines and treatments fast, which meant a massive surge in demand for NHP testing. At the same time, China, historically a massive supplier, “just went cold monkey,” as Puri puts it, cutting off 60% of the world's non-human primate supply. This double whammy sent prices soaring.

Puri notes the staggering jump: “They used to be 2 grand a monkey. When COVID happened, prices shot up... So it got to 20,000, 50,000 per monkey.” Imagine the impact on drug development budgets when a single input's cost multiplies by 25x. Companies like Charles River Labs, a research testing service with $4 billion in annual revenue, felt this pain directly. Their response? They bought an entire monkey breeding business “for $500 million just to control the supply better.” This wasn't a play for expansion; it was a desperate move to stabilize a critical bottleneck.

What to Do With This

Stop looking for the obvious opportunities. Instead, pull your last quarter's spending report. For your top three non-HR expenses over $10,000, ask: what's the 'monkey' behind that input? Map its supply chain. Identify single points of failure, geopolitical risks, or obscure dependencies. If that input's price skyrockets 20x overnight, how does it affect your business? Could you acquire that supplier, fund an alternative, or build a strategic reserve? The biggest wins often hide in the mundane, overlooked inputs that hold entire industries hostage.